Answers are grounded in this paper and cite their sources.
Expansion of primary liver stem cells/organoids derived directly from irreversibly damaged liver from patients with NASH opens up experimental avenues for personalized disease modeling and drug development that has the potential to slow human NASH progression and to counteract NASH-related SARS-CoV-2 effects.
No takes yet. Share an insight, caveat, or question.
McCarron et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: